On 22 and 23 May 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for two new formulations of Novo Nordisk’s semaglutide:
- Wegovy® pill (once-daily oral semaglutide 25 mg); and
- high-dose Wegovy® 7.2 mg (once-weekly injectable semaglutide) in a single-dose pen formulation,
The Wegovy® pill is the first oral GLP-1 treatment recommended for approval by CHMP for weight management in the EU. It follows the first-in-world US approval of the oral formulation by the FDA on 23 December 2025 and US launch of the Wegovy® pill on 5 January 2026. Eli Lilly’s Foundayo™ (orforglipron), the only other oral GLP-1 receptor therapy for weight loss, received US FDA approval on 1 April 2026 and became available to patients on 6 April 2026.
High dose Wegovy® expands the dosing options available in Europe, with Wegovy® currently available only as once-weekly treatment with three separate 2.4 mg injections administered one after each other. Novo Nordisk expects to launch Wegovy® 7.2 mg in a single-dose pen in Q3 2026 in Europe. Wegovy® 7.2 mg is already available in the US under the brand name Wegovy® HD.